Pyridine Carboxamide PDE4 Inhibitor for Brain Trauma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for brain trauma, such as those involving PDE 4 inhibitors, often induce emetogenic effects, making them unsuitable for clinical use despite potential efficacy.
Innovation Solution
The use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide, in its hydrate, solvate, base, or acid salt forms, for treating brain trauma, which avoids emetogenic effects at therapeutic doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PDE 4 inhibitors such as rolipram are administered to treat brain trauma, then therapeutic efficacy is improved, but emetogenic effects are induced that prevent clinical use
Solution Approach 1:
The patent modifies the chemical structure of PDE 4 inhibitors by changing molecular parameters (substituents on the pyridine ring, ester groups) to develop compounds that maintain therapeutic efficacy while reducing or eliminating emetogenic side effects. This is achieved through systematic structural modifications including varying R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20 groups as defined in the patent.
Solution Approach 2:
The patent applies local quality by making specific localized modifications to different regions of the PDE 4 inhibitor molecule. Different substituents are introduced at specific positions (R1-R20) to optimize the balance between therapeutic activity and reduction of emetogenic effects, allowing different parts of the molecule to have different functional properties.
2Reliability
If conventional PDE 4 inhibitors are used for brain trauma treatment, then anti-inflammatory effects are achieved, but clinical applicability is reduced due to side effects
Solution Approach 1:
The patent systematically varies chemical parameters of PDE 4 inhibitors including ester groups (R1-R4), aromatic substituents (R5-R10), and heterocyclic groups (R11-R20) to optimize the therapeutic window. This allows maintenance of anti-inflammatory efficacy while improving clinical applicability by reducing emetogenic side effects to acceptable levels.
Solution Approach 2:
The patent creates composite molecular structures combining different functional groups (pyridine rings, ester groups, aromatic substituents, heterocyclic moieties) in specific configurations. These composite structures achieve the dual objective of maintaining anti-inflammatory activity while minimizing emetogenic effects through synergistic interactions between different molecular components.
Data Source
AI summary
The invention relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the preparation of a medicament for use in the treatment of cranial traumas.